CNC

Business profile & competitive position

Centene Corp. (CNC) sits in the Healthcare sector, specifically the Medical – Healthcare Plans industry, and runs the largest U.S. managed-care franchise focused on underserved populations. Through Medicaid, Medicare Advantage, Prescription Drug Plans, Marketplace commercial coverage, and supplemental products, the company links 27.6 million members to care and non-medical supports such as food, housing, utilities, and transportation, often delivered under local brands like Health Net and Ambetter.

The 2025 revenue mix shows Medicaid at 57% of revenue, Commercial at 21%, Medicare at 19%, and Other at 3%, totaling $194.8 billion. Membership as of December 31, 2025, was 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members, making Centene the country’s largest insurer in all three categories. That scale, combined with multi-year state Medicaid contracts and federal Medicare/Marketplace approvals, is the company’s real competitive moat; it is not reflected in current profitability metrics, which are under pressure.

The net margin is -2.6% and return on equity is -24.0%. Those figures imply Centene is not currently converting its top-line scale into accounting profits. Still, operating cash flow was $5.1 billion in 2025, so the business is generating cash while it works through margin restoration.

Financial posture

Centene carries a market capitalization of $33.7 billion and trades at a negative P/E of -6.5. A negative P/E is simply a function of negative trailing earnings and should not be read as a cheapness signal; it confirms that GAAP earnings are negative rather than suggesting a discount.

The net margin of -2.6% and ROE of -24.0% reinforce the same point: shareholder profitability is currently negative. Beta is 1.11, so the stock historically moves slightly more than the broad market. At the September 14, 2026 snapshot, the stock price was $68.12, with the Relative Strength Index at 58.1 and the 50-day exponential moving average at $64.50, meaning price was about $3.62 above its short-term trend.

Compare the $5.1 billion operating cash flow to the $33.7 billion market cap and the implied cash flow yield is roughly 15%. That disconnect between GAAP losses and cash generation is one of the central facts traders anchor on when judging whether the reported loss is a temporary pricing correction or a deeper earnings-quality issue.

Strategic priorities & outlook

Centene’s most recent 10-K filing lays out several tangible priorities. The first is refining the Medicare footprint so it overlaps more closely with Medicaid operations, while expanding Dual-Eligible Special Needs Plans to drive long-term growth. The company is also keeping an enterprise-level focus on D-SNP products aligned with CMS requirements that run through 2030.

On the policy front, management says it will advocate for legislation that preserves affordable Medicaid and Marketplace coverage as well as cost-effective, high-quality care for PDP members. Operationally, the 2026 corrective Marketplace pricing actions are targeting states that cover 95% of Marketplace membership, and Ambetter Health Solutions/ICHRA-compatible off-exchange coverage is being expanded from 6 states to 13 states.

A separate corporate action worth watching is the definitive agreement signed in December 2025 to divest the remaining Magellan Health businesses, which would further simplify the portfolio around core government-sponsored health benefits.

Macro & geopolitical exposure

Because Centene is a Medicaid, Medicare, and Marketplace plan administrator, its core exposures are regulatory and political rather than commodity or currency-driven. Federal Medicaid match rates, CMS reimbursement rules, Medicare Advantage rate notices, and the structure of Affordable Care Act Marketplace subsidies all directly affect revenue and margins.

State-level Medicaid procurement is also a recurring risk: contracts are rebid periodically, and margin pressure can come from aggressive state pricing or benefit expansions. Healthcare cost inflation, provider rate negotiations, and pharmacy spending feed into medical-loss ratios. Interest-rate shifts matter indirectly through the investment income on reserves and through financing costs, but they are not the primary driver of the business model. Tariff and foreign-currency exposure is minimal because services are domestic.

Recent developments

The September 14, 2026, news flow includes two Zacks listicles that name Centene among healthcare and growth stocks: “4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike” and “Best Growth Stocks to Buy for September 14th.” A similar Zacks piece, “Best Growth Stocks to Buy for September 10th,” appeared on September 10, 2026.

Separately, on September 9, 2026, a Health Net-branded release via PR Newswire announced a $2 million investment aimed at creating more affordable homes for Stanislaus County residents. Health Net is one of Centene’s local-market brands, so the item shows how the company uses community-benefit spending to support brand positioning in key states.

Earnings behavior & post-earnings drift

Centene’s earnings track record over the last eight quarters is strong: it has beaten the consensus estimate in 7 of 8 reports, an 88% beat rate, with an average earnings surprise of 63.1%. Despite often large beats, the stock’s immediate next-day reaction has been inconsistent, which is a reminder that beating estimates does not guarantee a positive gap.

In the four most recent quarters, the company beat every time but posted mixed one-day moves. On July 28, 2026, EPS of $2.51 crushed the $1.09 estimate by 130.3%, yet the stock fell 3.27% the next day and only added 0.25% over the following five sessions. The April 28, 2026 report delivered EPS of $3.37 versus $2.23 estimated, a 51.1% beat, and the stock rose 8.9% the next day and 6.88% over five sessions. On February 6, 2026, EPS of -$1.19 beat the -$1.22007 estimate by 2.5%, with a next-day drop of 1.09% but a five-day gain of 5.51%. The October 29, 2025 quarter saw EPS of $0.50 versus an estimated -$0.14475, a 445.4% beat, yet the stock fell 6.21% the next day and 1.34% over five sessions.

Averaging the full eight-quarter sample, the five-day post-earnings drift is classified as “up,” posting an average gain of 2.83%. The next scheduled report is October 27, 2026, before the open, with a consensus EPS estimate of $0.07, a sharp retreat from the $2.51 reported last quarter and a number that suggests analysts are modeling some normalization after recent outperformance.

For a deeper dive into how Wall Street is currently interpreting these fundamentals around the upcoming October 27, 2026 report, traders can review the full institutional verdict and consensus wrap to see how analysts are weighting the margin recovery story against policy risk.